Brief: Ampio Announces Enrollment Completion For Intravenous COVID-19 Clinical Trial
04/09/2020 20:49
Sept 4 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO ANNOUNCES ENROLLMENT COMPLETION FOR INTRAVENOUS
("IV")
COVID-19 CLINICAL TRIAL & PROVIDES UPDATE ON OSTEOARTHRITIS OF
THE KNEE ("OAK") CLINICAL TRIAL
Source text for Eikon: urn:newsml:reuters.com:*:nPnbMqp2Pa
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank